TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31405091

Group type: EXPERIMENTAL
Intervention: Cold-water hand immersion (5 °C for 15 min)
Number of subjects: 10
Study: 30344180

Group type: EXPERIMENTAL
Intervention: Intravenous human albumin solution (HAS) administered to target serum albumin level of ≥35 g/L for up to 14 days or until discharge.
Number of subjects: 866

Group type: COMPARATOR
Intervention: Standard medical care (control group).
Number of subjects: 866
Study: 27633687

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin) prophylaxis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 50
Study: 23511280

Group type: EXPERIMENTAL
Intervention: LiDCO group (hemodynamic monitoring through lithium dilution cardiac output)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (without LiDCO monitoring)
Number of subjects: 21
Study: 21161260

Group type: EXPERIMENTAL
Intervention: Acetazolamide (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No acetazolamide (n = 25)
Number of subjects: 50
Study: 19217592

Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: NS with 5% dextrose (D5NS)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: NS with 10% dextrose (D10NS)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 289
Study: 17119004

Group type: EXPERIMENTAL
Intervention: Personalised 6 week, home based exercise and strategy programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study: 15540292

Group type: EXPERIMENTAL
Intervention: Vaginal posterior colporrhaphy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transanal rectoceleplasty
Number of subjects: 30
Study: 11146780

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (45 Gy concurrent radiotherapy and fluorouracil 225‐250 mg/m(2) per day for 5 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 12
Study: 9444509

Group type: EXPERIMENTAL
Intervention: Social worker supervision (group A)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No social worker supervision (group B)
Number of subjects: 600
Study: 8195686

Group type: EXPERIMENTAL
Intervention: Learning strategy instruction
Number of subjects: 33

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 33
Study: 3207531

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31841795

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly subcutaneous injection
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 28867355

Group type: EXPERIMENTAL
Intervention: Physical activity (at least 2.5h/wk)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Physical activity (at least 1.5h/wk)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Physical activity (at least 150min/week)
Number of subjects: 286
Study: 28282325

Group type: EXPERIMENTAL
Intervention: Survival scenario (manikin responded to appropriate resuscitation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Death scenario (manikin remained pulseless despite resuscitation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both scenarios (comparison of salivary cortisol levels)
Number of subjects: 42
Study: 25543183

Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 23047659

Group type: EXPERIMENTAL
Intervention: Worksite vaccination program
Number of subjects: 13520
Study: 20555256

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress-reduction training (8-week mindfulness-training course)
Number of subjects: 18
Study: 18338298

Group type: EXPERIMENTAL
Intervention: In-class and on-road education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waited for education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-road evaluation after education
Number of subjects: 0
Study: 21961489

Group type: EXPERIMENTAL
Intervention: Reference formulation of metformin hydrochloride (1,000 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test formulation of metformin hydrochloride (1,000 mg)
Number of subjects: 20
Study: 16143129

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid, 8‐10 mg/kg body weight daily (n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: cholestyramine, 8 g daily (n = 42)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 84

Group type: COMPARATOR
Intervention: cholestyramine
Number of subjects: 84
Study: 12392588

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine (C-replete)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (C-naïve)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C-replete
Number of subjects: 12
Study: 9475468

Group type: EXPERIMENTAL
Intervention: Physical Health Summary (PHS) score
Number of subjects: 2415

Group type: EXPERIMENTAL
Intervention: Mental Health Summary (MHS) score
Number of subjects: 2415
Study: 8076228

Group type: EXPERIMENTAL
Intervention: ondansetron (5 mg.m‐2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: metoclopramide (0.12 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo (saline solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 60
Study: 2574554

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily (qd)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily (bid)
Number of subjects: 392
Study: 12717127

Group type: EXPERIMENTAL
Intervention: 6.5 cm bent length in group A
Number of subjects: 379

Group type: COMPARATOR
Intervention: 8.5 cm bent length in group A
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 6.5 cm bent length in group B
Number of subjects: 379

Group type: COMPARATOR
Intervention: 8.5 cm bent length in group B
Number of subjects: 379
Study: 31272953

Group type: EXPERIMENTAL
Intervention: Binocular game
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Part-time patching
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined group (binocular game + patching)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Combined group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Patching
Number of subjects: 103
Study: 29091020

Group type: EXPERIMENTAL
Intervention: Nanobone (NB)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bio-Oss (BO)
Number of subjects: 14
Study: 26364667

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) for 12 hours after delivery
Number of subjects: 182

Group type: COMPARATOR
Intervention: Magnesium sulfate (MgSO4) for 24 hours after delivery
Number of subjects: 182
Study: 23759442

Group type: EXPERIMENTAL
Intervention: Alcohol delamination (ALD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Phototherapeutic keratectomy (PTK)
Number of subjects: 33
Study: 22719840

Group type: EXPERIMENTAL
Intervention: Intra‐operative anaesthetic intervention with BiSpectral index and cerebral oxygen saturation monitoring
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 192
Study: 20626269

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: Raloxifene with antiplatelet agents
Number of subjects: 10101

Group type: EXPERIMENTAL
Intervention: Raloxifene without antiplatelet agents
Number of subjects: 10101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study: 18308753

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) algorithm
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional pacemaker and implantable cardioverter‐defibrillator programming
Number of subjects: 600
Study: 15937619

Group type: EXPERIMENTAL
Intervention: Proximate PPH stapler
Number of subjects: 50

Group type: COMPARATOR
Intervention: LigaSure hemorrhoidectomy
Number of subjects: 50
Study: 12638114

Group type: EXPERIMENTAL
Intervention: Group 1 (preferred limb practice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2 (nonpreferred limb practice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 1 and Group 2
Number of subjects: 0
Study: 10607813

Group type: EXPERIMENTAL
Intervention: High-dose rhuMAb‐E25 (5.8 microg/kg/nanogram IgE/mL)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Low-dose rhuMAb‐E25 (2.5 microg/kg/nanogram IgE/mL)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Both rhuMAb‐E25 groups
Number of subjects: 317
Study: 8535917

Group type: EXPERIMENTAL
Intervention: High feedback
Number of subjects: 207

Group type: COMPARATOR
Intervention: Low feedback
Number of subjects: 207
Study: 1833682

Group type: EXPERIMENTAL
Intervention: Desogestrel (20 micrograms ethinyl estradiol + 150 micrograms desogestrel)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gestodene (30 micrograms ethinyl estradiol + 75 micrograms gestodene)
Number of subjects: 34
Study: 6109267

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30733037

Group type: EXPERIMENTAL
Intervention: Double-row repair with 2 standard suture anchors and 2 knotless anchor devices
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-row repair with suture anchors only
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Double-row anchor repair
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single-row repair
Number of subjects: 12
Study: 29899691

Group type: EXPERIMENTAL
Intervention: Real ctDCS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 6
Study: 26964505

Group type: EXPERIMENTAL
Intervention: SMS intervention (90 SMSes over 17 weeks)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study: 25225000

Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mood induction procedure
Number of subjects: 0
Study: 23249810

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate (CS; 13 subjects)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 4% nonoxynol-9 (N-9; 12 subjects)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hydroxyethylcellulose (HEC)-based 'universal' placebo (10 subjects)
Number of subjects: 35
Study: 20145608

Group type: EXPERIMENTAL
Intervention: Probiotic (2 capsules per day)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Probiotic (1 capsule + 1 placebo capsule per day)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (2 capsules per day)
Number of subjects: 255
Study: 18044193

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 38
Study: 16136646

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a and ribavirin
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Cirrhosis
Number of subjects: 1145
Study: 12503476

Group type: COMPARATOR
Intervention: Mechanical compression device (FemoStop)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 239
Study: 11331696

Group type: EXPERIMENTAL
Intervention: closed-loop FIO(2) control (cFIO(2))
Number of subjects: 14

Group type: COMPARATOR
Intervention: manual FIO(2) adjustments (mFIO(2))
Number of subjects: 14
Study: 9856652

Group type: COMPARATOR
Intervention: Continuous infusion 5-fluorouracil (5FU)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-fluorouracil with paclitaxel
Number of subjects: 87
Study: 8602900

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scope
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rembrandt Mouth Refreshing Rinse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clear Choice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water Control
Number of subjects: 30
Study: 2691808

Group type: EXPERIMENTAL
Intervention: 15 mg Quazepam (QZP) for 8 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Triazolam (TRZ) for 8 weeks
Number of subjects: 65
Study: 603221

Group type: EXPERIMENTAL
Intervention: Practolol (0.2 mg/kg body weight) with atropine (0.01 mg/kg body weight)
Number of subjects: 39
Study: 31809985

Group type: EXPERIMENTAL
Intervention: Omega-3 (oral Omega-3 2 g twice daily)
Number of subjects: 53
Study: 31292183

Group type: COMPARATOR
Intervention: 0 mg thiamine (control)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 1.2 mg thiamine
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 2.4 mg thiamine
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 10 mg thiamine
Number of subjects: 320
Study: 28167007

Group type: EXPERIMENTAL
Intervention: Sinuclean Nebules treatment administered by nasal douche (Rinowash) twice/day for 10 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Isotonic saline administered by nasal douche (Rinowash) twice/day for 10 days
Number of subjects: 61
Study: 25819209

Group type: EXPERIMENTAL
Intervention: Sharp needle
Number of subjects: 35

Group type: COMPARATOR
Intervention: Blunt needle
Number of subjects: 35
Study: 24032636

Group type: EXPERIMENTAL
Intervention: Diprifusor (ke0 0.26 min‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Base Primea (ke0 1.21 min‐1)
Number of subjects: 60
Study: 21804625

Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 204

Group type: COMPARATOR
Intervention: AuraOnce™
Number of subjects: 204
Study: 18543100

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Results sharing process
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Satisfaction with results sharing
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Anxiety after results sharing
Number of subjects: 167
Study: 16440357

Group type: EXPERIMENTAL
Intervention: Preemptive lamivudine therapy (100 mg daily from the start of TACL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no lamivudine therapy)
Number of subjects: 73
Study: 15214970

Group type: EXPERIMENTAL
Intervention: Neurosurgical procedures
Number of subjects: 68
Study: 11761792

Group type: EXPERIMENTAL
Intervention: Quality improvement model using academic detailing and electronic medical records (EMRs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control practices receiving copies of clinical practice guidelines and quarterly updates
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intervention practices receiving similar information and participating in regular site visits and investigator meetings
Number of subjects: 23
Study: 9132982

Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal tablets (2 x 100 mg once a day for 7 days)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: AVC suppositories (1.05 g sulfanilamide, 14 mg aminacrine hydrochloride, 140 mg allantoin twice a day for 7 days)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Oral metronidazole (2 g as a single oral dose)
Number of subjects: 168
Study: 8421182

Group type: EXPERIMENTAL
Intervention: Endotoxin (2 ng/kg of body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha (50 micrograms/m2)
Number of subjects: 0
Study: 3721054

Group type: EXPERIMENTAL
Intervention: RV11 (propionyl erythromycin mercaptosuccinate) 500 mg oral dose
Number of subjects: 0
Study: 31762222

Group type: EXPERIMENTAL
Intervention: PHILOS combined with fibular allograft
Number of subjects: 42

Group type: COMPARATOR
Intervention: PHILOS alone
Number of subjects: 42
Study: 29962591

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg i.v.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg i.v.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg and Dexamethasone 4 mg i.v.
Number of subjects: 90
Study: 26902549

Group type: EXPERIMENTAL
Intervention: Elevated admission shock index (n=321)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Admission shock index
Number of subjects: 791
Study: 24989060

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Duloxetine 20-120 mg/day
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Duloxetine (various doses)
Number of subjects: 428
Study: 22393128

Group type: EXPERIMENTAL
Intervention: MTX and prednisone (10 mg/d)
Number of subjects: 236

Group type: COMPARATOR
Intervention: MTX and placebo
Number of subjects: 236
Study: 20141566

Group type: EXPERIMENTAL
Intervention: High dose atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual dose of simvastatin
Number of subjects: 0
Study: 17932844

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hyaluronate (BD Multivisc)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soft shell technique (Biolon and Viscoat)
Number of subjects: 30
Study: 16127109

Group type: EXPERIMENTAL
Intervention: Hospital in the Home (HITH) treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 100
Study: 12789224

Group type: EXPERIMENTAL
Intervention: Cetirizine 0.25 mg/kg orally twice daily for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10229311

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin: 0.1 IU/kg body weight/day of neutral protamine hagedorn (NPH) insulin once a day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin
Number of subjects: 10
Study: 8553397

Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation practice
Number of subjects: 0
Study: 1859050

Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prednisone plus placebo (n = 13)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine (adjusted for age)
Number of subjects: 27
Study: 6574528

Group type: EXPERIMENTAL
Intervention: Dexamethasone administered at 1900h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexamethasone administered at 2300h
Number of subjects: 6
Study: 4028724

Group type: EXPERIMENTAL
Intervention: MLCu 250
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: MLCu 375
Number of subjects: 549

Group type: COMPARATOR
Intervention: MLCu 250 and MLCu 375
Number of subjects: 549
Study: 30371190

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Placebo/Ezetimibe
Number of subjects: 4983
Study: 26654211

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for recurrent MDD, 12-14 weeks duration
Number of subjects: 523

Group type: COMPARATOR
Intervention: Continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo for higher risk patients (n = 241, 83%)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Continuation-phase therapy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Lower and higher risk groups
Number of subjects: 523
Study: 24637345

Group type: EXPERIMENTAL
Intervention: Intervention condition (alternating between seated and standing work posture every 30 min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control condition (seated work posture)
Number of subjects: 23
Study: 23357715

Group type: EXPERIMENTAL
Intervention: Gluten-containing diet (GCD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gluten-free diet (GFD)
Number of subjects: 45
Study: 20856584

Group type: EXPERIMENTAL
Intervention: Novel filtration device
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 19106471

Group type: EXPERIMENTAL
Intervention: 4 mm of gutta‐percha retained
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 5 mm of gutta‐percha retained
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 6 mm of gutta‐percha retained
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (5 mm positive control)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (5 mm negative control)
Number of subjects: 126
Study: 16607678

Group type: EXPERIMENTAL
Intervention: Splenectomy during total gastrectomy (104 patients)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Total gastrectomy without splenectomy (103 patients)
Number of subjects: 207
Study: 11579985

Group type: EXPERIMENTAL
Intervention: Distraction (listening to an audiotape) during the first hour of exposure treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exposure without distraction during the first hour of exposure treatment
Number of subjects: 60
Study: 9539197

Group type: EXPERIMENTAL
Intervention: Contingent group (watching VCR movies and playing video games contingent upon riding the bicycle)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (all physical and sedentary activities freely available)
Number of subjects: 14
Study: 7742260

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 2646252

Group type: EXPERIMENTAL
Intervention: Destagnation (radiation plus Destagnation)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (radiation only)
Number of subjects: 188
Study: 1101614

Group type: EXPERIMENTAL
Intervention: etidocaine 1% with adrenaline (5 mug/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: bupivacaine 0.5% with adrenaline (5 mug/ml)
Number of subjects: 40
Study: 29615751

Group type: EXPERIMENTAL
Intervention: InSAR analysis using data from Envisat, ALOS‐1, TerraSAR‐X, and Sentinel‐1
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) on 200 randomly selected time series of the LUC
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hydro‐thermal model using InSAR scores from PCA
Number of subjects: 68
Study: 27175810

Group type: EXPERIMENTAL
Intervention: Cordless Sonicision™ (Covidien, Mansfield, MA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wired HARMONIC ACE®+ (Ethicon Endo‐Surgery Inc., Cincinnati, OH)
Number of subjects: 30